[go: up one dir, main page]

IS2980B - Aðferðir við að framleiða 4-[[4-[[4-(2-sýanóetenýl)-2,6-dímetýlfenýl]amínó]-2-pýrmídínýl]amínó]bensónítríl - Google Patents

Aðferðir við að framleiða 4-[[4-[[4-(2-sýanóetenýl)-2,6-dímetýlfenýl]amínó]-2-pýrmídínýl]amínó]bensónítríl

Info

Publication number
IS2980B
IS2980B IS7621A IS7621A IS2980B IS 2980 B IS2980 B IS 2980B IS 7621 A IS7621 A IS 7621A IS 7621 A IS7621 A IS 7621A IS 2980 B IS2980 B IS 2980B
Authority
IS
Iceland
Prior art keywords
amino
cyanoethyl
benzonitrile
dimethylphenyl
pyrimidinyl
Prior art date
Application number
IS7621A
Other languages
English (en)
Other versions
IS7621A (is
Inventor
Philippe Robert Schils Didier
Josephus Maria Willems Joannes
Petrus Anna Maria Jozef Medaer Bart
Therese Jeanne Pasquier Elisabeth
Adriaan Jan Janssen Paul
Heeres Jan
Gerardus George Leenders Ruben
Emile Georges Guillemont Jérome
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31725448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2980(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of IS7621A publication Critical patent/IS7621A/is
Publication of IS2980B publication Critical patent/IS2980B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/20—Preparation of carboxylic acid nitriles by dehydration of carboxylic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
IS7621A 2002-08-09 2004-12-29 Aðferðir við að framleiða 4-[[4-[[4-(2-sýanóetenýl)-2,6-dímetýlfenýl]amínó]-2-pýrmídínýl]amínó]bensónítríl IS2980B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02078306 2002-08-09
PCT/EP2003/050366 WO2004016581A1 (en) 2002-08-09 2003-08-07 Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile

Publications (2)

Publication Number Publication Date
IS7621A IS7621A (is) 2004-12-29
IS2980B true IS2980B (is) 2017-09-15

Family

ID=31725448

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7621A IS2980B (is) 2002-08-09 2004-12-29 Aðferðir við að framleiða 4-[[4-[[4-(2-sýanóetenýl)-2,6-dímetýlfenýl]amínó]-2-pýrmídínýl]amínó]bensónítríl

Country Status (26)

Country Link
US (3) US7399856B2 (is)
EP (1) EP1529032B1 (is)
JP (1) JP4822707B2 (is)
KR (2) KR101086678B1 (is)
CN (4) CN101481356B (is)
AR (1) AR040964A1 (is)
AU (1) AU2003266413B2 (is)
BR (1) BR0313545B1 (is)
CA (2) CA2686429C (is)
CL (1) CL2010000284A1 (is)
CY (1) CY1114428T1 (is)
DK (1) DK1529032T3 (is)
EA (1) EA007953B1 (is)
ES (1) ES2422196T3 (is)
HR (1) HRP20050104B1 (is)
IL (1) IL166710A (is)
IS (1) IS2980B (is)
MX (1) MXPA05001541A (is)
MY (1) MY144894A (is)
NO (1) NO330013B1 (is)
NZ (1) NZ538611A (is)
PL (1) PL208533B1 (is)
PT (1) PT1529032E (is)
SI (1) SI1529032T1 (is)
TW (1) TWI314146B (is)
WO (1) WO2004016581A1 (is)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
CN101481356B (zh) * 2002-08-09 2012-07-11 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
BR0316680A (pt) * 2002-11-28 2005-10-18 Schering Ag Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
WO2005123662A1 (en) * 2004-06-18 2005-12-29 Janssen Pharmaceutica N.V. Modified heck reaction
EA011036B1 (ru) * 2004-09-02 2008-12-30 Янссен Фармацевтика Н.В. Фумарат 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
EP1632232B3 (en) * 2004-09-02 2022-03-30 Janssen Pharmaceutica NV Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
KR101284361B1 (ko) * 2004-09-02 2013-07-15 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
CN101056673A (zh) * 2004-09-02 2007-10-17 詹森药业有限公司 4－[[4－[[4－(2－氰基乙烯基)－2,6－二甲基苯基]氨基]－2－嘧啶基]氨基]苄腈的盐酸盐
US7314962B2 (en) * 2005-04-15 2008-01-01 E. I. Du Pont De Nemours & Co. Alkylation of aromatic compounds
CA2609716C (en) 2005-05-26 2014-10-14 Tibotec Pharmaceuticals Ltd. Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitrile
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
SI2175857T1 (sl) * 2007-07-12 2014-01-31 Janssen R&D Ireland Kristalna oblika (E) 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino) 2-pirimidinil)amino)benzonitrila
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
EP2643294B1 (en) * 2011-04-15 2016-08-24 Emcure Pharmaceuticals Limited An improved rilpivirine process
US9126949B2 (en) 2011-04-25 2015-09-08 Hetero Research Foundation Process for rilpivirine
CA2848631C (en) * 2011-09-16 2019-10-01 Hetero Research Foundation Rilpivirine hydrochloride
WO2013170421A1 (zh) * 2012-05-14 2013-11-21 上海迪赛诺药业有限公司 利匹韦林盐酸盐醇化物多晶型物及其制备方法
WO2013179105A1 (en) * 2012-06-01 2013-12-05 Laurus Labs Private Limited Improved process for preparation of rilpivirine and pharmaceutically acceptable salts thereof
ES2664094T3 (es) 2012-07-12 2018-04-18 Hetero Research Foundation Procedimiento de preparación de rilpivirina utilizando un intermedio nuevo
CZ201532A3 (cs) 2015-01-21 2015-02-25 Zentiva, K.S. Způsob výroby vysoce čistého Rilpivirinu a jeho solí
CN106008366A (zh) * 2016-05-25 2016-10-12 山东大学 一种利匹韦林的制备方法
CA3039562A1 (en) 2016-10-24 2018-05-03 Janssen Sciences Ireland Unlimited Company Dispersible compositions
US20210380540A1 (en) 2018-10-25 2021-12-09 Minakem Process for the preparation of rilpivirine
CN110526873B (zh) * 2019-08-15 2022-09-16 复旦大学 氰乙烯基取代的苯并二芳基嘧啶类化合物及其制备方法和用途
WO2021104487A1 (en) 2019-11-29 2021-06-03 Aptorum Therapeutics Limited Composition including rilpivirine and use thereof for treating tumors or cancer
CN112010810B (zh) * 2020-09-09 2024-01-30 瑞阳制药股份有限公司 一锅法制备高纯度利匹韦林中间体的方法
CN112778214A (zh) * 2021-01-13 2021-05-11 安徽贝克联合制药有限公司 用于合成利匹韦林的中间体、其合成方法和利匹韦林的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
JPS5490121A (en) 1977-11-28 1979-07-17 Boettcher Barry Neutral copper bonded body and antiinflaming agent
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CN1198655C (zh) 1995-11-23 2005-04-27 詹森药业有限公司 通过熔体挤出法制备的环糊精固体混合物
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
HU230522B1 (hu) 1998-03-27 2016-10-28 Janssen Pharmaceutica N.V HIV-gátló pirimidinszármazékok
DE69943247D1 (de) 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
JP2000035628A (ja) 1998-07-16 2000-02-02 Konica Corp ハロゲン化銀写真感光材料
AU5438299A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
HU227453B1 (en) 1998-11-10 2011-06-28 Janssen Pharmaceutica Nv Hiv replication inhibiting pyrimidines, and pharmaceutical compositions containing them
BR0008804A (pt) 1999-03-09 2002-04-16 Upjohn Co 4-oxo-4, 7-dihidrotieno [2,3-b] piridina-5-carboxamidas como agentes antivirais
ID30460A (id) 1999-04-15 2001-12-06 Bristol Myers Squibb Co Inhibitor-inhibitor protein siklik tirosin kinase
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
SI1225874T1 (sl) 1999-09-24 2006-06-30 Janssen Pharmaceutica Nv Protivirusne trdne disperzije
JP2003532635A (ja) 2000-02-17 2003-11-05 アムジエン・インコーポレーテツド キナーゼ阻害薬
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
ES2542326T3 (es) 2000-05-08 2015-08-04 Janssen Pharmaceutica Nv Inhibidores de la replicación del VIH
US6596729B2 (en) * 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
KR100638954B1 (ko) 2001-03-02 2006-10-25 스미스클라인 비참 코포레이션 역전사 효소 억제제로서의 벤조페논
US6949544B2 (en) 2001-03-29 2005-09-27 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
JP2005507874A (ja) 2001-08-29 2005-03-24 ユーエムディー， インコーポレイテッド 癌治療のための化学療法剤及び膜流出システム阻害剤の経膣送達
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CN1290893C (zh) 2002-05-03 2006-12-20 詹森药业有限公司 聚合物微乳状液
CN101481356B (zh) 2002-08-09 2012-07-11 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base

Also Published As

Publication number Publication date
NZ538611A (en) 2007-03-30
CN102225902A (zh) 2011-10-26
IL166710A (en) 2010-12-30
AR040964A1 (es) 2005-04-27
EA200500325A1 (ru) 2005-06-30
CL2010000284A1 (es) 2010-08-20
NO330013B1 (no) 2011-02-07
US20060167253A1 (en) 2006-07-27
HK1081527A1 (en) 2006-05-19
NO20050524L (no) 2005-02-01
CA2686429C (en) 2010-11-16
MY144894A (en) 2011-11-30
US7399856B2 (en) 2008-07-15
AU2003266413B2 (en) 2009-04-02
JP2005537303A (ja) 2005-12-08
KR101140785B1 (ko) 2012-05-03
US7705148B2 (en) 2010-04-27
HK1129671A1 (en) 2009-12-04
KR101086678B1 (ko) 2011-11-25
CN1681774A (zh) 2005-10-12
TW200418810A (en) 2004-10-01
IL166710A0 (en) 2006-01-15
WO2004016581A1 (en) 2004-02-26
AU2003266413A1 (en) 2004-03-03
JP4822707B2 (ja) 2011-11-24
KR20100127889A (ko) 2010-12-06
CN102702111A (zh) 2012-10-03
BR0313545B1 (pt) 2021-07-27
CN102702111B (zh) 2014-12-17
PL208533B1 (pl) 2011-05-31
US20070191407A1 (en) 2007-08-16
US7563922B2 (en) 2009-07-21
CA2493794C (en) 2010-05-25
CN100554245C (zh) 2009-10-28
DK1529032T3 (da) 2013-07-08
EP1529032A1 (en) 2005-05-11
MXPA05001541A (es) 2005-04-19
SI1529032T1 (sl) 2013-08-30
CN102225902B (zh) 2013-04-24
HK1161869A1 (en) 2012-08-10
CN101481356B (zh) 2012-07-11
EA007953B1 (ru) 2007-02-27
TWI314146B (en) 2009-09-01
CA2493794A1 (en) 2004-02-26
US20080167464A1 (en) 2008-07-10
ES2422196T3 (es) 2013-09-09
HK1174922A1 (en) 2013-06-21
CY1114428T1 (el) 2016-08-31
IS7621A (is) 2004-12-29
HRP20050104A2 (en) 2006-03-31
BR0313545A (pt) 2005-07-12
HRP20050104B1 (hr) 2014-02-14
PL373679A1 (en) 2005-09-05
PT1529032E (pt) 2013-07-11
EP1529032B1 (en) 2013-04-24
CA2686429A1 (en) 2004-02-26
CN101481356A (zh) 2009-07-15
KR20050040906A (ko) 2005-05-03

Similar Documents

Publication Publication Date Title
IS2980B (is) Aðferðir við að framleiða 4-[[4-[[4-(2-sýanóetenýl)-2,6-dímetýlfenýl]amínó]-2-pýrmídínýl]amínó]bensónítríl
LTC1632232I2 (lt) 4[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska
DK1259513T3 (da) Ny krystallinsk form af N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutaminsyre og fremgangsmåder til dets fremstilling
DK2175857T3 (da) Krystallinsk form af (e) 4-[[4-[[4-(2-cyanoethenyl)-2.6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitril
DK1610780T3 (da) Cykliske protein-tyrosin-kinasehæmmere
EP1534268A4 (en) TYROSINE KINASE INHIBITORS
EE200300400A (et) Pürimidiiniühendid, nende valmistamismeetod ning kasutamine
DK1578731T3 (da) Fremgangsmåde til fremstilling af pyrimidinforbindelser
PL1632232T6 (pl) Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
CR9031A (es) Clorhidrato de 4-((4-((4-2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidinil)amino)benzonitrilo
AP2487A (en) Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
NI200700069A (es) Fumarato de 4-((4-((4- (2-cianoetenil)-2,6-dimetilfenil)amino)-2- pirimidinil) amino) benzonitrilo
IL164377A (en) Methods of preparation of 2-(7-chloro-1,8-naphthyridine-2yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone
ITRM20010736A1 (it) Impianto osteointegrato di lunghezza aggiustabile e un kit per la suapreparazione.
ITMI20020620A1 (it) Procedimento per la preparazione di alchil-benzoati per esterificazione di benzoil-fluoruri